Table 3B.

Univariate and multivariate analyses for relapse‐free survival in the application cohort.

	Univariate analysis		Multivariate analysis
	HR (95% CI)	P value	HR (95% CI)	P value
Age, years	1.032 (0.983–1.084)	0.204
Sex, male	1.025 (0.976–1.076)	0.327
Smoke, former/current	1.183 (0.827–1.693)	0.358
Drink, former/current	1.048 (0.663–1.655)	0.841
Co‐morbidity, yes	0.818 (0.580–1.153)	0.251
Respiratory co‐morbidity, yes	1.379 (0.440–4.320)	0.581
Cardiovascular co‐morbidity, yes	0.814 (0.567–1.168)	0.264
Diabetes, yes	0.820 (0.465–1.443)	0.490
Time from symptom onset to hospitalization, month	1.001 (0.954–1.050)	0.975
Neutrophil‐lymphocyte ratio	1.478 (1.061–2.060)	0.021
Platelet‐lymphocyte ratio	1.000 (0.999–1.002)	0.656
Albumin, g/L	0.989 (0.981–0.998)	0.021
Haemoglobin, g/L	0.996 (0.989–1.002)	0.193
Weight, kg	0.990 (0.976–1.004)	0.154
BMI, kg/m2	0.809 (0.596–1.098)	0.173
SMI, cm2/m2	0.977 (0.959–0.995)	0.011	0.978 (0.960–0.997)	0.025
Appetite loss, yes	1.564 (1.097–2.230)	0.013
Cancer site
Liver	Reference		Reference
Gallbladder	2.025 (1.326–3.094)	0.001	2.927 (1.870–4.584)	0.000
Pancreas	2.406 (1.322–4.380)	0.004	2.372(1.296–4.341)	0.005
Stomach	1.756 (0.899–3.429)	0.099	2.128 (1.077–4.203)	0.030
Colorectum	1.220 (0.844–1.763)	0.290	1.324 (0.911–1.925)	0.142
Cancer stage, n (%)
I	Reference		Reference
II	1.262 (0.741–2.149)	0.392	1.386 (0.811–2.370)	0.233
III	3.113 (1.937–5.004)	0.000	4.155 (2.528–6.829)	0.000
IV	6.297 (3.830–10.352)	0.000	6.659 (4.035–10.989)	0.000
Histologic type, differentiated	0.984 (0.970–0.999)	0.037
Abnormal tumour biomarker, yes	1.237 (0.915–1.674)	0.167
Cancer cachexia risk score	4.576 (1.843–11.360)	0.001	4.793 (1.798–12.779)	0.002

Abbreviations: BMI, body mass index; SMI, skeletal muscle index; HR, hazard ratio; CI, confidence interval.